The Sarat Chandarlapaty Lab
Research
The goal of our research program is to understand the detailed mechanisms by which a cancer cell can develop resistance to therapies targeting its oncogenic driver; and to exploit those findings to elucidate the biology of cancer and identify more effective treatments for cancer patients. The focus of this work has been on signaling networks emanating from the hormone receptor, ERa, and the receptor tyrosine kinase, HER2. These two signals play a dominant role in cancers of the breast, with roughly 85% of all tumors driven by one or both of these receptors. Whereas drugs targeting these signals have major benefits in patients, resistance to therapy is frequently encountered. Our studies have centered on (1) understanding how cancers evolve to resist therapies against ER, CDK4/6, HER2, and PI3K and (2) development of mechanism-based drugs or treatment strategies that can prevent or overcome these modes of resistance.
People
Sarat Chandarlapaty, MD, PhD
Naddisy Foundation Chair in Breast Cancer Research
- Physician-scientist Sarat Chandarlapaty studies the regulation of growth factor signaling networks in cancer.
- PhD, University of North Carolina
- chandars@mskcc.org
- Email Address
- View physician profile
- Physician profile
Members
Achievements
- Professor of Medicine, Weill Cornell Medical College and Weill Cornell Cell and Developmental Biology Program
- Member Memorial Sloan Kettering Cancer Center, Department of Medicine and Human Oncology and Pathogenesis Program